Perritt Capital Management Inc.'s holdings in AbbVie were worth $517,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the stock. First PREMIER Bank boosted its stake in shares of AbbVie by 1,850.0% in the third quarter. Penserra Capital Management LLC now owns 1,764 shares of the company's stock valued at $111,000 after buying an additional 882 shares during the last quarter. Gyroscope Capital Management Group LLC raised its stake in AbbVie by 5.9% in the fourth quarter. St. Louis Trust Co raised its stake in AbbVie by 0.6% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,701,437 shares of the company's stock worth $296,520,000 after buying an additional 182,686 shares during the last quarter. Moloney Securities Asset Management LLC acquired a new stake in shares of AbbVie during the fourth quarter valued at approximately $1,075,000. Pinnacle Wealth Management Advisory Group LLC now owns 9,275 shares of the company's stock valued at $585,000 after buying an additional 50 shares during the last quarter. Kempen Capital Management N.V. purchased a new stake in AbbVie during the third quarter worth $19,889,000. Insiders sold 139,599 shares of company stock valued at $9,038,322 over the last quarter.
Shares of AbbVie Inc (NYSE:ABBV) traded up 0.12% during mid-day trading on Monday, hitting $65.24.
Stock is now moving with a positive distance from the 200 day simple moving average of approximately 5.11%, and has a solid year to date (YTD) performance of 5.11% which means the stock is constantly adding to its value from the previous fiscal year end price. AbbVie Inc has a 1-year low of $55.06 and a 1-year high of $68.12. The company has a market capitalization of $103.86 billion, a P/E ratio of 17.95 and a beta of 1.57.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 27th. (ABBV) is $71/share according to the consensus of analysts working on the stock, with an expected EPS of $1.26/share for the current quarter. The firm earned $6.78 billion during the quarter, compared to analysts' expectations of $6.92 billion.
AbbVie Inc. (ABBV) is now showing its ROA (Return on Assets) of 9.4%. The business's revenue was up 6.0% on a year-over-year basis. Analysts anticipate that AbbVie Inc will post $5.50 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, May 15th. Investors of record on Thursday, April 13th will be given a dividend of $0.64 per share.
The stock now has its Annual Dividend of $2.56 and an annual Dividend Yield of 3.93 Percent. The ex-dividend date of this dividend is Tuesday, April 11th. AbbVie's dividend payout ratio is now 70.52%. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/03/leuthold-group-llc-sells-7623-shares-of-abbvie-inc-abbv.html. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & worldwide copyright legislation.
Several research firms have recently issued reports on ABBV. Vetr raised shares of AbbVie from a "buy" rating to a "strong-buy" rating and set a $68.83 price objective for the company in a research report on Wednesday, December 21st. Finally, Jefferies Group LLC restated a "buy" rating and issued a $90.00 price objective (up previously from $4.30) on shares of AbbVie in a report on Tuesday, March 7th. Societe Generale raised shares of AbbVie from a "sell" rating to a "hold" rating in a report on Wednesday, March 22nd. William Blair reissued an "outperform" rating and issued a $76.00 price objective on shares of AbbVie in a research report on Thursday, December 8th. AbbVie presently has a consensus rating of "Buy" and an average target price of $70.69. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. The company now has an average rating of "Buy" and an average price target of $70.69.
In other AbbVie news, Chairman Richard A. Gonzalez sold 72,016 shares of AbbVie stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $64.25, for a total transaction of $4,627,028.00. Following the completion of the transaction, the chairman now owns 369,113 shares in the company, valued at $23,715,510.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Laura J. Schumacher sold 40,000 shares of the firm's stock in a transaction that occurred on Friday, March 10th. The stock was sold at an average price of $65.29, for a total transaction of $335,068.28.